These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35776191)

  • 41. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
    Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
    Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
    Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
    J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas.
    Kumar A; Pathak P; Purkait S; Faruq M; Jha P; Mallick S; Suri V; Sharma MC; Suri A; Sarkar C
    Cancer Genet; 2015 Mar; 208(3):91-5. PubMed ID: 25794445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vestigial-Like 3 Plays an Important Role in Osteoblast Differentiation by Regulating the Expression of Osteogenic Transcription Factors and BMP Signaling.
    Yuan H; Ikegame M; Fukuhara Y; Takemoto F; Yu Y; Teramachi J; Weng Y; Guo J; Yamada D; Takarada T; Li Y; Okamura H; Zhang B
    Calcif Tissue Int; 2022 Sep; 111(3):331-344. PubMed ID: 35750933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma.
    Hofvander J; Tayebwa J; Nilsson J; Magnusson L; Brosjö O; Larsson O; Vult von Steyern F; Mandahl N; Fletcher CD; Mertens F
    Clin Cancer Res; 2015 Feb; 21(4):864-9. PubMed ID: 25516889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma.
    Antonescu CR; Sung YS; Chen CL; Zhang L; Chen HW; Singer S; Agaram NP; Sboner A; Fletcher CD
    Genes Chromosomes Cancer; 2014 Feb; 53(2):183-93. PubMed ID: 24285434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diverse
    Stangl C; Post JB; van Roosmalen MJ; Hami N; Verlaan-Klink I; Vos HR; van Es RM; Koudijs MJ; Voest EE; Snippert HJG; Kloosterman WP
    Mol Cancer Res; 2020 Apr; 18(4):537-548. PubMed ID: 31911540
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transcriptional and posttranscriptional regulation of the SMC-selective blood pressure-associated gene, ARHGAP42.
    Mangum KD; Freeman EJ; Magin JC; Taylor JM; Mack CP
    Am J Physiol Heart Circ Physiol; 2020 Feb; 318(2):H413-H424. PubMed ID: 31886719
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TEAD1 inhibits prolactin gene expression in cultured human uterine decidual cells.
    Kessler CA; Bachurski CJ; Schroeder J; Stanek J; Handwerger S
    Mol Cell Endocrinol; 2008 Nov; 295(1-2):32-8. PubMed ID: 18775765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The transcription factor TEAD1 represses smooth muscle-specific gene expression by abolishing myocardin function.
    Liu F; Wang X; Hu G; Wang Y; Zhou J
    J Biol Chem; 2014 Feb; 289(6):3308-16. PubMed ID: 24344135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.
    Knezevich SR; McFadden DE; Tao W; Lim JF; Sorensen PH
    Nat Genet; 1998 Feb; 18(2):184-7. PubMed ID: 9462753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas.
    Hélias-Rodzewicz Z; Pérot G; Chibon F; Ferreira C; Lagarde P; Terrier P; Coindre JM; Aurias A
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1161-71. PubMed ID: 20842732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Profiling of gene fusion involving targetable genes in Chinese gastric cancer.
    Liu ZH; Zhu BW; Shi M; Qu YR; He XJ; Yuan HL; Ma J; Li W; Zhao DD; Liu ZC; Wang BM; Wang CY; Tao HQ; Ma TH
    World J Gastrointest Oncol; 2022 Aug; 14(8):1528-1539. PubMed ID: 36160735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses.
    Botton T; Talevich E; Mishra VK; Zhang T; Shain AH; Berquet C; Gagnon A; Judson RL; Ballotti R; Ribas A; Herlyn M; Rocchi S; Brown KM; Hayward NK; Yeh I; Bastian BC
    Cell Rep; 2019 Oct; 29(3):573-588.e7. PubMed ID: 31618628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.
    Chakraborty R; Burke TM; Hampton OA; Zinn DJ; Lim KP; Abhyankar H; Scull B; Kumar V; Kakkar N; Wheeler DA; Roy A; Poulikakos PI; Merad M; McClain KL; Parsons DW; Allen CE
    Blood; 2016 Nov; 128(21):2533-2537. PubMed ID: 27729324
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
    Corcoran RB; Dias-Santagata D; Bergethon K; Iafrate AJ; Settleman J; Engelman JA
    Sci Signal; 2010 Nov; 3(149):ra84. PubMed ID: 21098728
    [TBL] [Abstract][Full Text] [Related]  

  • 59. VGLL3 activates inflammatory responses by inducing interleukin-1α secretion.
    Takakura Y; Hori N; Terada N; Machida M; Yamaguchi N; Takano H; Yamaguchi N
    FASEB J; 2021 Nov; 35(11):e21996. PubMed ID: 34679187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma.
    Puls F; Agaimy A; Flucke U; Mentzel T; Sumathi VP; Ploegmakers M; Stoehr R; Kindblom LG; Hansson M; Sydow S; Arbajian E; Mertens F
    Am J Surg Pathol; 2020 May; 44(5):594-606. PubMed ID: 31913156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.